Search results
Why FDA Panel Rejected MDMA Therapy—And What’s Next For Psychedelic Medicine
Forbes· 1 day agoHigh hopes that psychedelic medicines were finally on the pathway to regulation were dashed last...
FDA panel rejects MDMA-assisted therapies for PTSD despite high hopes from veterans
Fox News· 2 days agoA U.S. Food and Drug Administration (FDA) panel rejected MDMA-based treatments for post-traumatic...
MDMA’s Future As A Treatment For PTSD Is In Question
Inverse· 4 days agoWhile the FDA will still vote separately on MDMA, it generally follows the recommendation of its advisors, so its unlikely the novel treatment will gain approval... drug is ...
Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.
Motley Fool via Yahoo Finance· 4 days agoDespite their votes, committee members signaled that they weren't opposed to an MDMA-based therapy...
After FDA setback, psychedelic drugmakers distance themselves from a pioneer
Washington Post· 6 days agoIn making this case, other potential applicants described the approach by Lykos, and its nonprofit...
Psilocybin Therapy Pilot Program Bill Introduced in California
High Times· 2 days agoA psilocybin treatment bill was recently introduced on June 6 by California Sen. Brian W. Jones and...
Should You Buy the Dip on Compass Pathways Stock?
Motley Fool via Yahoo Finance· 3 days agoUnlike most medicines intended for psychiatry, COMP360 has...for psychological support can squeeze the most efficacy out of the psychoactive component of...
The Potential Benefits and Dangers of Rewiring the Brain
Mercola· 7 days agoThe panel includes neuroscientists Takao Hensch and John Krakauer, as well as entrepreneur Brett Wingeier, co-founder and CEO of Magnus Medical. This capacity could potentially heal
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
KOLR - KSFX Ozarks· 4 days agoNRx Pharmaceuticals has now reached the 9-month stability point with its ketamine formulation (NRX-100) and has initiated 3 manufacturing lots for future drug release. The short-term need for ...
